Literature DB >> 15487896

Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry.

Kevin P Bateman1, Jennifer Baker, Mark Wilke, Justin Lee, Tammy Leriche, Carmai Seto, Stephen Day, Nathalie Chauret, Marc Ouellet, Deborah A Nicoll-Griffith.   

Abstract

Protein covalent labeling can be an undesirable property of compounds being studied in drug discovery programs. Identifying such compounds relies on the use of radiolabeled material, which requires an investment in time and resources not typically expended until later in the discovery process. We describe the detection of covalent adducts to cytochrome P450 3A4, the most abundant and important P450 from a human and drug discovery viewpoint, using liquid chromatography mass spectrometry. The technique is illustrated using L-754,394 and 6',7'-dihydroxybergamottin, two known inhibitors of P450 3A4. Mass spectrometry of the intact apoprotein as well as the adducted protein is demonstrated. Such methodology may provide the means for screening compounds for covalent protein binding without the use of a radiolabel. It also provides direct information about mechanism-based inhibitors in terms of extent, stoichiometry, and nature of the adduct(s) (mass shift). This information may provide a means for understanding the mechanism of covalent labeling earlier in a drug discovery environment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15487896     DOI: 10.1021/tx0498861

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  8 in total

1.  Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Authors:  Hsia-Lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

2.  Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.

Authors:  Amanda K Bolles; Rina Fujiwara; Erran D Briggs; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2014-10-01       Impact factor: 3.922

3.  Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.

Authors:  Leslie D Nagy; Catherine S Mocny; Laura E Diffenderfer; David J Hsi; Brendan F Butler; Evan J Arthur; Kyle J Fletke; Jairam R Palamanda; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2011-03-21       Impact factor: 3.922

4.  Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study.

Authors:  Ju Liu; Qian Li; Xiaofeng Yang; Richard B van Breemen; Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2005-09       Impact factor: 3.739

Review 5.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 6.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

7.  A crosslinker based on a tethered electrophile for mapping kinase-substrate networks.

Authors:  Megan M Riel-Mehan; Kevan M Shokat
Journal:  Chem Biol       Date:  2014-04-17

8.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.